Quoin Pharmaceuticals Ltd. (QNRX), a clinical-stage pharmaceutical company, on Monday announced additional positive interim data from its ongoing clinical study of QRX003 in Netherton Syndrome, a rare and severe skin condition.
The latest data follows the first subject's 12-week dosing period with QRX003, demonstrating significant clinical improvements across all key endpoints, including skin severity, itching, and overall symptom severity.
QRX003 is designed to restore the skin barrier in Netherton Syndrome patients by targeting the underlying mechanism related to the deficiency of the LEKTI protein, which leads to excessive skin shedding and a compromised skin barrier. It has shown strong efficacy in improving the skin condition associated with Netherton Syndrome, with patients reporting high satisfaction scores in their overall experience.
Importantly, no safety concerns have been identified to date in any of the ongoing studies.
Quoin Pharmaceuticals CEO Dr. Michael Myers commented about the results, emphasizing that the improvement observed in the skin appearance of the subject demonstrates QRX003's potential to provide substantial clinical benefits.
The company is preparing to launch a broader clinical trial for QRX003, which will be conducted by Dr. Amy Paller at Northwestern University.
This trial, aimed at gathering further clinical data, is expected to play a crucial role in supporting Quoin's New Drug Application or NDA for QRX003, aiming to become the first approved treatment for Netherton Syndrome.
Quoin's pipeline includes other innovative products targeting rare and orphan diseases.
The company remains committed to developing treatments that address the unmet needs of patients with conditions like Netherton Syndrome, which currently has no approved therapies.
The company anticipates further updates on their clinical progress in 2025, aiming for a transformative impact in the treatment of Netherton Syndrome and other rare dermatologic conditions.
Currently, QNRX is trading at $0.67 down by 3.34%.
For comments and feedback: editorial@rttnews.com